Applied Proteomics
The API assets could enable more data-intensive, machine learning-based approaches to healthcare, said a principal at DiscernDx investor Khosla Ventures.
Applied Proteomics Sells Assets to DiscernDx for $1.85M
DiscernDx, which is backed by Khosla Ventures, stepped in to purchase API's assets after lender Square 1 Bank asserted a lien on the company late last year.
The firm is looking for outside partners to tackle test commercialization as it begins to bring its second-generation colorectal cancer assay to market.
The test, which the company aims to launch in the next few months, offers a boost in specificity compared to its existing SimpliPro Colon proteomic test.
Company officials said that they have seen favorable reorder rates and coverage decisions since launching the 11-protein colorectal cancer test in late 2015.